hrp0089fc1.6 | Adrenals & HPA Axis | ESPE2018

A Novel Stem Cell Model for the Triple A Syndrome

Da Costa Alexandra Rodrigues , Qarin Shamma , Bradshaw Teisha Y. , Watson David , Prasad Rathi , Barnes Michael R. , Metherell Louise A. , Chapple J. Paul , Skarnes William C. , Storr Helen L.

Triple A syndrome (AAAS) is a rare, incurable, recessive disorder, characterised by achalasia, alacrima, adrenal failure and a neurodegenerative phenotype. The AAAS gene encodes ALADIN, is a nuclear pore complex (NPC) protein necessary for nuclear import of DNA protective molecules, important for redox homeostasis. ALADIN’s role is not fully characterised: its discovery at the centrosome and the endoplasmic reticulum suggests a role outside the NPC. To date, the ...

hrp0095p1-113 | Growth and Syndromes | ESPE2022

Development and testing of a novel ‘GrowthMonitor’ Smartphone App for growth monitoring and the detection of growth disorders

Thaventhiran Thilipan , Orr Joanna , K. Morris Joan , Harding Vincent , Hsu Ann , Dunkel Leo , Chapple Paul , L. Storr Helen

Background: Childhood growth is an indicator of health/well-being. Growth monitoring identifies treatable conditions in apparently healthy children and prevents inappropriate referrals. Systematic growth monitoring is not currently a UK priority and growth disorders are frequently diagnosed late.Objective: Develop and test the accuracy of GrowthMonitor, an app which enables families to measure a child’s height at h...

hrp0097p1-483 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Incidence of Perinatal Stress Hyperinsulinism Requiring Diazoxide Treatment in Newborn Infants

Rafferty Deborah , Truong Lisa , Nedrelow J , Thornton Paul

Background: The incidence of perinatal stress hyperinsulinism (PSHI) requiring diazoxide treatment is estimated to be 1:12,000 (Hoe et al., 2006). Diazoxide is used to treat PSHI, but it has been shown to have adverse effects including pulmonary hypertension. Gray et al, reported that of 1.25 million infants admitted to NICUs for hypoglycemia over a period of 18 years, only 1066 received diazoxide suggesting 1:1172 babies had HI however 92% o...

hrp0095p1-500 | GH and IGFs | ESPE2022

A patient-centric approach to connected health solutions in paediatric growth hormone therapy

Halabi Ammar , Martin Blaine , Koledova Ekaterina , Giunti Guido , Dimitri Paul

Background: There is a clear need for improved patient-centric approaches in the treatment of chronic conditions, including paediatric growth hormone deficiency (GHD). Greater understanding of the patient’s treatment journey has the potential to inform clinical decisions and to improve clinical- and patient-reported outcomes. Connected Health (CH) combines state-of-the-art technologies, tools, methodologies and analytics to create new patient-centric hea...

hrp0094p1-161 | Growth B | ESPE2021

Continued Safety and Efficacy of Weekly Lonapegsomatropin (TransCon hGH) for up to Two Years in Children with Growth Hormone Deficiency (GHD)

Aghajanova Elena M. , Casella Samuel J. , Nadgir Ulhas , Hofman Paul , Saenger Paul , Song Wenjie , Mao Meng , Chessler Steven , Komirenko Allison S. , Beckert Michael , Shu Aimee D. , Thornton Paul S. , Maniatis Aristides K. ,

Lonapegsomatropin (TransCon hGH) is an investigational once-weekly prodrug of somatropin for the treatment of GHD. Previous trials in treatment-naïve (52-week heiGHt Trial) and treatment-experienced children (26-week fliGHt Trial) have reported the efficacy and safety of lonapegsomatropin. Subjects were eligible to enter the open-label extension enliGHten Trial, which continues to evaluate weekly lonapegsomatropin in pediatric GHD. In heiGHt, treatment-naïve subjects...

hrp0095rfc3.2 | Early Life and Multisystem Endocrinology | ESPE2022

The Hypoglycaemia Error Grid: a UK-wide Consensus on CGM Accuracy Assessment in Hypoglycaemia due to Congenital Hyperinsulinism

Worth Chris , J Dunne Mark , Salomon-Estebanez Maria , Harper Simon , W Nutter Paul , Dastamani Antonia , Senniappan Senthil , Banerjee Indraneel

Background and Objective: Continuous Glucose Monitoring (CGM) is gaining in popularity for patients with paediatric hypoglycaemia disorders such as Congenital Hyperinsulinism (CHI), but no standard measures of accuracy or associated clinical risk are available. A small number of studies have shown suboptimal accuracy of CGM in CHI but assessments have been inconsistent, incomplete and offer no measure of clinical application. Error grids that categorise clinic...

hrp0094p1-61 | Diabetes B | ESPE2021

Timing of Hypoglycaemia in Patients with Hyperinsulinism (HI): Extension of the Digital Phenotype

Worth Chris , Harper Simon , Salomon-Estebanez Maria , O’Shea Elaine , Nutter Paul , Dunne Mark J , Banerjee Indraneel ,

Background: Hyperinsulinism (HI) due to excess and dysregulated insulin secretion is the most common cause of severe and recurrent hypoglycaemia in childhood. High cerebral glucose utilisation in the early hours results in high risk of hypoglycaemia for people with diabetes and carries a significant risk of brain injury. Prevention of hypoglycaemia is the cornerstone of management for HI but the risk of hypoglycaemia at night or indeed the timing of hypoglycae...

hrp0086s6.1 | Prevention of childhood obesity | ESPE2016

Long-term Consequences of Childhood Obesity: The Impact of Genes and Lifestyle

Franks Paul

In most complex traits, susceptibility to certain risk exposures and response to clinical interventions in is under genetic control, a concept broadly termed “gene-environment interaction”. Although in animals and in plants there is evidence supporting this notion, in humans most evidence is confined to rare monogenic disorders. In complex diseases like type 2 diabetes and obesity, interactions between genetic and environmental risk factors are likely to begin very e...

hrp0094wg7.3 | ESPE Working Group for Paediatric Endocrine Nurses (ESPEN) Symposium | ESPE2021

Nursing care for the child with gender dysphoria

Carruthers Paul ,

This presentation will provide an insight into the Gender identity Development service (GIDS) endocrine pathway. The service has experienced a difficult year with well documented legal challenges; these will be briefly presented highlighting the impact this has had on patient care. It is important when working with gender incongruent young people to be aware of the use of appropriate pronouns, co-occurring difficulties and the importance of advocacy in our nursing practice. Th...

hrp0094p1-26 | Diabetes A | ESPE2021

Efficacy and Tolerability of GLP-1 Receptor Agonists in Children and Adolescents with Obesity

Ryan Paul ,

Background: Rates of pediatric obesity are on a concerning upward trajectory globally, with the prevalence approaching 1 in 5 children and adolescents aged 2-19 years in the United States. As a direct consequence of this obesity surge, we will continue to experience a substantial adult cardiometabolic burden. Although public health measures to optimize lifestyle interventions and reduce culpable environmental exposures are the primary target for governments an...